News
-
FDA Approves Remicade To Treat Ulcerative Colitis In Children 6 Years And Older
9/30/2011
The U.S. Food and Drug Administration recently approved Remicade (infliximab) to treat moderately to severely active ulcerative colitis (UC) in children 6 years and older who have had inadequate response to conventional therapy.
-
Trident Pharmaceuticals Announces Initiation Of Phase 1a Clinical Study Of HF1020
9/21/2011
Trident Pharmaceuticals Inc., a biotechnology company developing therapies for autoimmune diseases and allergic conditions, today announced the initiation of a Phase 1a study for HF1020, a first in class recombinant protein with immunomodulatory activity.
-
AstraZeneca Announces Top-Line Results From SATURN Study
9/6/2011
AstraZeneca today announced top-line results from SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin Versus AtorvastatiN). SATURN was designed to measure the impact of CRESTOR (rosuvastatin) 40 mg and atorvastatin 80 mg on the progression of atherosclerosis in high risk patients.
-
NEW Aerosol Exposure Unit For Mice & Rats
9/2/2011
This system is ideally suited for exposing groups of mice or rats to aerosolized powders or liquids. This is Harvard Apparatus-Hugo Sachs Electronik's first system dedicated to inhalation studies in awake animal models.
-
FDA Approves Adcetris To Treat Two Types Of Lymphoma
8/26/2011
The U.S. Food and Drug Administration recently approved Adcetris (brentuximab vedotin) to treat Hodgkin lymphoma (HL) and a rare lymphoma known as systemic anaplastic large cell lymphoma (ALCL).
-
Cytokinetics Announces Phase I And Phase IIa Clinical Trial Results For Omecamtiv Mecarbil Published In The Journal Lancet
8/23/2011
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the publication of results from two clinical trials of omecamtiv mecarbil, a novel cardiac myosin activator, in the August 20, 2011 issue of the journal Lancet.
-
New Two-Drug Approach To Treat Type Of Respiratory Disease
8/11/2011
A therapy combining two existing drugs could provide an effective new approach for treating patients with pleural infections, a serious condition where infected fluid builds up in the space between the ribs and lungs.
-
FDA Approves Xarelto To Reduce Risk Of Blood Clots After Hip, Knee Replacements
7/8/2011
On July 1, the U.S. Food and Drug Administration approved Xarelto (rivaroxaban) to reduce the risk of blood clots, deep vein thrombosis (DVT), and pulmonary embolism (PE) following knee or hip replacement surgery.
This website uses cookies to ensure you get the best experience on our website. Learn more